---
annotation-target: blood.2022016782.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-22T13:44:04.602Z","updated":"2022-09-22T13:44:04.602Z","document":{"title":"blood.2022016782.pdf","link":[{"href":"urn:x-pdf:f920a9fe073783aaef5ad0d031e7b504"},{"href":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf"}],"documentFingerprint":"f920a9fe073783aaef5ad0d031e7b504"},"uri":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","selector":[{"type":"TextPositionSelector","start":140,"end":171},{"type":"TextQuoteSelector","exact":"MRD dynamics during maintenance","prefix":"776-0545editorial@hematology.org","suffix":" for improved prognostication of"}]}]}
>```
>%%
>*%%PREFIX%%776-0545editorial@hematology.org%%HIGHLIGHT%% ==MRD dynamics during maintenance== %%POSTFIX%%for improved prognostication of*
>%%LINK%%[[#^4vfmald7e3e|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4vfmald7e3e


>%%
>```annotation-json
>{"created":"2022-09-22T13:53:16.544Z","text":"伊沙佐米","updated":"2022-09-22T13:53:16.544Z","document":{"title":"blood.2022016782.pdf","link":[{"href":"urn:x-pdf:f920a9fe073783aaef5ad0d031e7b504"},{"href":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf"}],"documentFingerprint":"f920a9fe073783aaef5ad0d031e7b504"},"uri":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","selector":[{"type":"TextPositionSelector","start":8945,"end":8954},{"type":"TextQuoteSelector","exact":" ixazomib","prefix":"rrently 50): MRD volatility with","suffix":" v placebo maintenance  Authors:"}]}]}
>```
>%%
>*%%PREFIX%%rrently 50): MRD volatility with%%HIGHLIGHT%% ==ixazomib== %%POSTFIX%%v placebo maintenance  Authors:*
>%%LINK%%[[#^6550qpn7r5l|show annotation]]
>%%COMMENT%%
>伊沙佐米
>%%TAGS%%
>
^6550qpn7r5l


>%%
>```annotation-json
>{"created":"2022-09-22T13:53:53.082Z","updated":"2022-09-22T13:53:53.082Z","document":{"title":"blood.2022016782.pdf","link":[{"href":"urn:x-pdf:f920a9fe073783aaef5ad0d031e7b504"},{"href":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf"}],"documentFingerprint":"f920a9fe073783aaef5ad0d031e7b504"},"uri":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","selector":[{"type":"TextPositionSelector","start":12105,"end":12233},{"type":"TextQuoteSelector","exact":"Ixazomib prolonged progression-free survival in patients who were MRD+ prior to maintenance and at a 14-month landmark analysis.","prefix":"risk of disease progression. •  ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%risk of disease progression. •%%HIGHLIGHT%% ==Ixazomib prolonged progression-free survival in patients who were MRD+ prior to maintenance and at a 14-month landmark analysis.== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^azujqa0ld5w|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^azujqa0ld5w


>%%
>```annotation-json
>{"created":"2022-09-22T13:57:55.499Z","updated":"2022-09-22T13:57:55.499Z","document":{"title":"blood.2022016782.pdf","link":[{"href":"urn:x-pdf:f920a9fe073783aaef5ad0d031e7b504"},{"href":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf"}],"documentFingerprint":"f920a9fe073783aaef5ad0d031e7b504"},"uri":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","selector":[{"type":"TextPositionSelector","start":12521,"end":13058},{"type":"TextQuoteSelector","exact":"Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of MRD dynamics in 1280 transplant-eligible and -ineligible patients from the TOURMALINE-MM3 and -MM4 randomized, placebo-controlled, phase 3 studies of 2-year ixazomib maintenance. MRD status at randomization showed independent prognostic value (median progression-free survival [PFS]: 38.6 vs 15.6 months in MRD– vs MRD+ patients, HR 0.47). However, MRD dynamics during maintenance provided more detailed risk stratification","prefix":"ation in multiple myeloma (MM). ","suffix":". A 14-month landmark analysis s"}]}]}
>```
>%%
>*%%PREFIX%%ation in multiple myeloma (MM).%%HIGHLIGHT%% ==Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of MRD dynamics in 1280 transplant-eligible and -ineligible patients from the TOURMALINE-MM3 and -MM4 randomized, placebo-controlled, phase 3 studies of 2-year ixazomib maintenance. MRD status at randomization showed independent prognostic value (median progression-free survival [PFS]: 38.6 vs 15.6 months in MRD– vs MRD+ patients, HR 0.47). However, MRD dynamics during maintenance provided more detailed risk stratification== %%POSTFIX%%. A 14-month landmark analysis s*
>%%LINK%%[[#^6jgdcgefxnf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6jgdcgefxnf


>%%
>```annotation-json
>{"created":"2022-09-22T14:05:57.714Z","updated":"2022-09-22T14:05:57.714Z","document":{"title":"blood.2022016782.pdf","link":[{"href":"urn:x-pdf:f920a9fe073783aaef5ad0d031e7b504"},{"href":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf"}],"documentFingerprint":"f920a9fe073783aaef5ad0d031e7b504"},"uri":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220922/blood.2022016782.pdf","selector":[{"type":"TextPositionSelector","start":15182,"end":15382},{"type":"TextQuoteSelector","exact":"Historically, MRD has been evaluated at specific single timepoints during therapy. However, interest is growing in the use of serial assessments to improve risk stratification based on MRD dynamics.13","prefix":"tailor treatment duration.11,12 ","suffix":" Patients attaining sustained MR"}]}]}
>```
>%%
>*%%PREFIX%%tailor treatment duration.11,12%%HIGHLIGHT%% ==Historically, MRD has been evaluated at specific single timepoints during therapy. However, interest is growing in the use of serial assessments to improve risk stratification based on MRD dynamics.13== %%POSTFIX%%Patients attaining sustained MR*
>%%LINK%%[[#^4kn542svs5t|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4kn542svs5t
